Realising a 1D topological gauge theory in an optically dressed BECĪuthors: A. B 106, 045141 (2022)Įncoding a one-dimensional topological Gauge theory in a Raman-coupled Bose-Einstein condensateĪuthors: C. Splitting of topological charge pumping in an interacting two-component fermionic Rice-Mele Hubbard modelĪuthors: E. Invisible flat bands on a topological chiral edgeĪuthors: Youjiang Xu, Irakli Titvinidze, Walter Hofstetter Preprint: arXiv:2204.11946v1 Uhrig, Walter Hofstetter, Mohsen Hafez-Torbati Preprint: /abs/2209.04730 Weitenberg Preprint: arXiv:2207.03811 (2022)Īntiferromagnetic Chern insulator in centrosymmetric systemsĪuthors: Morad Ebrahimkhas, Götz S. doi: 10.1001/-frequency optical lattice for dynamic lattice-geometry controlĪuthors: M.N. Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer: A nonrandomized phase 1 clinical trial. Oaknin A., Tinker A.V., Gilbert L., Samouëlian V., Mathews C., Brown J., Barretina-Ginesta M.-P., Moreno V., Gravina A., Abdeddaim C., et al. 1044P–Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study. O’Malley D., Marabelle A., De Jesus-Acosta A., Piha-Paul S.A., Arkhipov A., Longo F., Motola-Kuba D., Shapira-Frommer R., Geva R., Rimel B.J., et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study. doi: 10.1016/j.ygyno.2020.06.025.Ĭhung H.C., Ros W., Delord J.P., Perets R., Italiano A., Shapira-Frommer R., Manzuk L., Piha-Paul S.A., Xu L., Zeigenfuss S., et al. Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial. Ledermann J.A., Colombo N., Oza A.M., Fujiwara K., Birrer M.J., Randall L.M., Poddubskaya E.V., Scambia G., Shparyk Y.V., Lim M.C., et al.
Leonhard hofstetter update#
Roche Provides Update on Phase III Study of Tecentriq in Women with Advanced Stage Ovarian Cancer.
RECIST biomarker immune checkpoint inhibitor immunotherapy overweight.
Pretherapeutic BMI therefore appears to be a promising readily available biomarker to identify patients with PD-L1-positive and/or MMR-deficient gynecologic malignancies who could particularly benefit from CPI treatment. All results could be confirmed in the multivariate analyses. Associations between a BMI increase per 5 kg/m 2 and overall response rate (ORR complete + partial response), disease control rate (DCR ORR + stable disease), progression-free (PFS), and overall survival (OS) were assessed. Thirty-six patients receiving at least four courses were included in the final analysis. We evaluated patients with programmed cell death ligand 1 (PD-L1) positive and, in endometrial cancer, also mismatch repair deficient (MMR) gynecologic malignancies, who received the PD-1 inhibitor pembrolizumab as monotherapy (200 mg fixed-dose q3 w) from 2017 to 2020 (n = 48). Therefore, we aimed to assess the predictive and prognostic value of pretherapeutic body mass index (BMI) for recurrent gynecologic cancer patients as previously validated for other solid tumors. Despite increasing clinical interest in adapting checkpoint inhibitor (CPI) therapies for patients with gynecologic malignancies, no accurate clinical biomarkers to predict therapy response and prognosis are currently available.
0 kommentar(er)
